XLRN Acceleron Pharma Inc

Acceleron to Host Educational Webcast on Facioscapulohumeral Muscular Dystrophy (FSHD) with Leading Researcher and Provide Overview of ACE-083 Phase 2 Trial

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that it will host an educational webinar on facioscapulohumeral muscular dystrophy (FSHD) and the Company’s Phase 2 clinical trial of ACE-083 in FSHD patients. The webinar will be led by neuromuscular disease expert, Jeffrey Statland, M.D., M.P.H., and Acceleron management, at 10:00 a.m. EDT on Friday, October 28, 2016.

Dr. Statland is an assistant professor of neurology at the University of Kansas Medical Center with both clinical and research training in neuromuscular diseases. His primary research interest is in FSHD, one of the most prevalent forms of muscular dystrophy, characterized by a progressive loss of muscle strength. During the webinar, Dr. Statland will provide an overview of FSHD, its clinical manifestations and unmet medical need. Acceleron management will provide an overview of ACE-083 and the design of the upcoming Phase 2 clinical trial. At the end of the presentation, Dr. Statland and Acceleron management will be available to answer questions from the call participants.

Conference Call and Webcast Details

 
Date:               Friday, October 28, 2016
Time: 10:00 a.m. (EDT)

Participants can access the live conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the Acceleron FSHD Call.

The live webcast can be accessed on the Investors page of the Company's website at www.acceleronpharma.com.

A replay of the webcast will be available approximately two hours after the event on the Acceleron website.

About ACE-083

ACE-083 is a therapeutic candidate that acts as a ligand trap for members in the transforming growth factor-beta (TGF-β) superfamily involved in the regulation of muscle mass and strength. ACE-083 has been designed to increase muscle mass and strength selectively in the muscles into which the drug is administered. Acceleron is developing ACE-083 for diseases in which improved muscle strength in a specific set of muscles may provide a clinical benefit, such as facioscapulohumeral muscular dystrophy.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on social media: @AcceleronPharma and LinkedIn.

EN
13/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Acceleron Pharma Inc

ACCELERON PHARMA reduced its risk exposure resulting in an upgrade to ...

ACCELERON PHARMA (US), a company active in the Biotechnology industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date September 21, 2021, the closing price ...

Acceleron Pharma Inc: 1 director sold after exercising options/sold

A director at Acceleron Pharma Inc sold after exercising options/sold 11,864 shares at 140.185USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direc...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Key Resistance As we have outlined in recent weeks, our base case continues to be for near-term consolidation while the market is in a “wait-and-see” phase as it relates to states re-opening. The S&P 500 is again testing key resistance at the 61.8% Fibonacci retracement level of 2934.49 and also the 2950-3000 level we previously identified. We continue to have concerns that lead us to believe the market is not yet out of the woods, however these concerns are counterbalanced ...

ROP ROPER TECHNOLOGIES INC.
LOGI LOGITECH INTERNATIONAL S.A.
NOW SERVICENOW INC.
XLRN ACCELERON PHARMA INC
WST WEST PHARMACEUTICAL SERVICES INC.
WIX WIX.COM LTD.
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TWOU 2U INC.
TECH BIO-TECHNE CORPORATION
STMP STAMPS.COM INC.
SRPT SAREPTA THERAPEUTICS INC.
SPLK SPLUNK INC.
SP8 SPARTAN MOTORS INC.
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
RRC RANGE RESOURCES CORPORATION
RNG RINGCENTRAL INC. CLASS A
QDEL QUIDEL CORPORATION
PRLB PROTO LABS INC.
PODD INSULET CORPORATION
NVDA NVIDIA CORPORATION
NERV MINERVA NEUROSCIENCES
NDSN NORDSON CORPORATION
NBIX NEUROCRINE BIOSCIENCES INC.
MPWR MONOLITHIC POWER SYSTEMS INC.
LOPE GRAND CANYON EDUCATION INC.
IPHI INPHI CORPORATION
IPGP IPG PHOTONICS CORPORATION
IIVI II-VI INCORPORATED
IDXX IDEXX LABORATORIES INC.
HZNP HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
HALO HALOZYME THERAPEUTICS INC.
FTNT FORTINET INC.
FFIV F5 NETWORKS INC.
FAST FASTENAL COMPANY
ECOM CHANNELADVISOR CORP
EBS EMERGENT BIOSOLUTIONS INC.
CTSO CYTOSORBENTS
CTMX CYTOMX THERAPEUTICS INC.
CTLT CATALENT INC
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
CGNX COGNEX CORPORATION
AUDC AUDIOCODES LTD.
ATVI ACTIVISION BLIZZARD INC.
ATRC ATRICURE INC.
AMPH AMPHASTAR PHARMACEUTICALS INC
ALRM ALARM.COM HOLDINGS INC.
ALLT ALLOT LTD
AKBA AKEBIA THERAPEUTICS INC.
ABMD ABIOMED INC.
IRBT IROBOT CORPORATION
ENB. ENBRIDGE INC.
SWKS SKYWORKS SOLUTIONS INC.
AEM. AGNICO EAGLE MINES LIMITED
ACLS AXCELIS TECHNOLOGIES INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
ENPH ENPHASE ENERGY INC.
ENTG ENTEGRIS INC.
LSCC LATTICE SEMICONDUCTOR CORPORATION
THO THOR INDUSTRIES INC.
TREX TREX COMPANY INC.
CENTA CENTRAL GARDEN & PET CO A
EVBG EVERBRIDGE INC.
UTHR UNITED THERAPEUTICS CORPORATION
X UNITED STATES STEEL CORPORATION
COUP COUPA SOFTWARE INC.
CRSP CRISPR THERAPEUTICS AG
IRTC IRHYTHM TECHNOLOGIES INC.
ASML ASML HOLDING N.V.
MDGL MADRIGAL PHARMACEUTICALS
ZLAB ZAI LAB LTD. SPONSORED ADR
MDB MONGODB INC. CLASS A
AAPL APPLE INC.
WGO WINNEBAGO INDUSTRIES INC.
ACMR ACM RESEARCH
KRYS KRYSTAL BIOTECH INC
DBX DROPBOX INC. CLASS A
BTAI BIOXCEL THERAPEUTICS
TENB TENABLE HOLDINGS
CNST CONSTELLATION PHARMACEUTICALS
YMAB Y-MABS THERAPEUTICS
ALLO ALLOGENE THERAPEUTICS
TBIO TRANSLATE BIO
MRNA MODERNA INC.
AVTR AVANTOR INC.
NBSE NEUBASE THERAPEUTICS
GNMSY GENMAB A/S
UI UBIQUITI INC.
DT DYNATRACE INC.
AXLA AXCELLA HEALTH
DDOG DATADOG INC CLASS A
TWST TWIST BIOSCIENCE
ADPT ADAPTIVE BIOTECHNOLOGIES CORP.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch